Other products
Ventipulmin
Active substance
ATC code
Species
Horses.
Indications
Treatment of respiratory disease in horses where it is considered that airway obstruction due to bronchospasm and/or accumulation of mucus is a contributing factor, and improved muco-ciliary clearance is desirable. To be used alone or as adjuvant therapy.
In particular:
i) Acute, sub-acute and chronic respiratory allergies.
ii) Acute, sub-acute and chronic infections where the presence of mucus and/or micro-organisms may stimulate bronchospasm or cause airway obstruction and thus an increase in airway resistance. For example; bronchitis, bronchiolitis and bronchopneumonia alone, or associated with equine influenza and other viral respiratory diseases.
iii) Chronic Obstructive Pulmonary Disease (COPD).
In cases accompanied by bacterial infection the administration of antimicrobial agents is recommended.
Dose to be administered and administration route
Administer by slow intravenous injection at a dose of 2.7 ml per 100 kg bodyweight twice daily for as long as necessary. This is equivalent to twice daily administration of 0.8 micrograms clenbuterol hydrochloride per kg bodyweight.
Avoid the introduction of contamination during use.
Adverse reactions
Horses:
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Muscle tremor1,2, Increased sweating1 |
|
Undetermined frequency (cannot be estimated from the available data): |
Peripheral vasodilation1,3 |
1Transient following intravenous administration, ‘bolus’ effect may have occurred, may be minimised by administering the product slowly.
2Mild
3Feature exhibited by all beta-adrenergic drugs
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Dispensing
POM-V - Prescription Only Medicine – Veterinarian
TRUSTED SOURCE
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Ventipulmin Solution for injection 30 micrograms/ml
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Active substances:
Clenbuterol hydrochloride 30 micrograms Excipients:
|
Qualitative composition of excipients and other constituents |
Quantitative composition if that information is essential for proper administration of the veterinary medicinal product |
|
Benzyl Alcohol (E1519) |
10 mg/ml |
|
Sodium Chloride |
|
|
Hydrochloric Acid (Dilute) (for pH adjustment) |
|
|
Water for Injections |
|
Clear colourless solution.
3. CLINICAL INFORMATION
3.1 Target species
Horses.
3.2 Indications for use for each target species
Treatment of respiratory disease in horses where it is considered that airway obstruction due to bronchospasm and/or accumulation of mucus is a contributing factor, and improved muco-ciliary clearance is desirable. To be used alone or as adjuvant therapy.
In particular:
i) Acute, sub-acute and chronic respiratory allergies. ii) Acute, sub-acute and chronic infections where the presence of mucus and/or micro-organisms may stimulate bronchospasm or cause airway obstruction and thus an increase in airway resistance. For example; bronchitis, bronchiolitis and bronchopneumonia alone, or associated with equine influenza and other viral respiratory diseases. iii) Chronic Obstructive Pulmonary Disease (COPD).
In cases accompanied by bacterial infection the administration of antimicrobial agents is recommended.
3.3 Contraindications None.
3.4 Special warnings
Do not use in horses with known cardiac disease.
3.5 Special precautions for use
Special precautions for safe use in the target species: Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
This veterinary medicinal product contains clenbuterol hydrochloride, a betaβ-agonist. Take care to avoid skin contact. In case of accidental skin contact, wash affected area thoroughly. If irritation occurs/persists seek medical advice and show the package leaflet or the label to the physician.
Take care to avoid eye contact. In the case of accidental eye contact, flush thoroughly with clean water and seek medical advice and show the package leaflet or the label to the physician.
Do not eat, drink or smoke when using the product.
Wash hands thoroughly after using the product.
Accidental self-injection may produce tachycardia and tremor. These effects may be reversed by the use of a non-selective beta-blocker. In case of accidental selfinjection, avoid driving if possible and seek medical advice immediately. Show the package leaflet or the label to the physician.
People with known hypersensitivity to clenbuterol should avoid contact with the veterinary medicinal product.
Special precautions for the protection of the environment:
Not applicable.
3.6 Adverse events Horses:
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
|
|
Undetermined frequency (cannot be estimated from the available data): |
Peripheral vasodilation1,[3] |
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
3.7 Use during pregnancy, lactation or lay
If used during pregnancy, treatment must be discontinued at the expected time of delivery, since uterine contractions may be abolished under its influence.
3.8 Interaction with other medicinal products and other forms of interaction
This veterinary medicinal antagonises the effects of prostaglandin F2-alpha and oxytocin.
This veterinary medicinal is antagonised by β-adrenergic blocking agents.
3.9 Administration routes and dosage
Administer by slow intravenous injection at a dose of 2.7 ml per 100 kg bodyweight twice daily for as long as necessary. This is equivalent to twice daily administration of 0.8 micrograms clenbuterol hydrochloride per kg bodyweight.
Avoid the introduction of contamination during use.
3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)
See section 3.6 for likely clinical effects. In case of accidental overdose, a β-blocker such as propanolol may be used.
3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable.
3.12 Withdrawal periods
Meat and offal: 28 days.
Not authorised for use in animals producing milk for human consumption.
4. PHARMACOLOGICAL INFORMATION
4.1 ATCvet code: QR03CC13
The product contains the active ingredient clenbuterol hydrochloride, which is a sympathomimetic amine with a high degree of selectivity for the β2-receptor sites in the body, thus providing intense bronchodilating properties with minimum effect on the cardiovascular system. It has been shown to stimulate muco-ciliary clearance in horses.
The effects on pulmonary function and clinical response have been assessed in clinical trials with horses suffering from a variety of respiratory conditions.
A marked decrease in intrathoracic pressure, a decrease in respiratory rate, an initial decrease followed by an increase in arterial oxygen partial pressure and clinical improvements were observed. In addition, a significant reduction in resistance to airflow and a clinical improvement in the animals respiratory pattern were seen.
<4.2 Pharmacodynamics>
<4.3 Pharmacokinetics>
5. PHARMACEUTICAL PARTICULARS
5.1 Major incompatibilities
None known.
5.2 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life after first opening the immediate packaging: 28 days
5.3 Special precautions for storage
Do not store above 25 °C.
Protect from light.
Keep the container in the outer carton.
5.4 Nature and composition of immediate packaging
50 ml amber glass injection vial (Ph Eur. Type II), with pink bromobutyl rubber stopper and aluminium crimp cap.
Pack size:
Cardboard box containing 1 vial of 50 ml.
5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Medicines should not be disposed of via wastewater.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local
requirements and with any national collection systems applicable to the veterinary medicinal product concerned.
6. NAME OF THE MARKETING AUTHORISATION HOLDER
Boehringer Ingelheim Animal Health UK Limited
7. MARKETING AUTHORISATION NUMBER
Vm 08327/5067
8. DATE OF FIRST AUTHORISATION
22 August 1994
9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS
October 2026
10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT
Veterinary medicinal product subject to prescription.
Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.
Gavin Hall Approved: 20 October 2026
| Art. Nr. | 08327/4309 |
|---|---|
| GTIN | • • • • • • • • • 6898 |
